

13. (Amended) A method of increasing the antithrombotic activity of mammalian blood relative to the anticoagulant activity comprising administering to a mammal in need of treatment for thrombosis an oligoheteropolysaccharide comprising depolymerized heparin having an average molecular weight of about 2600 to about 5500 daltons determined by the Somogy method in comparison with commercial heparin and having sulfate groups in the quantity and in the positions characteristic of heparin, which oligoheteropolysaccharide displays greater antithrombotic activity than anticoagulant activity.

REMARKS

The undersigned spoke with the examiner over the phone on January 10, 1988. The amendments listed above are being made in accordance with the examiner's suggestions.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue.

Date:	Test	15 19DA	

Respectfully submitted,

Kevin M. Foley, Attorney Registration No. 31,307 Hepar Industries, Inc.

P.O. Box 338

Franklin, Ohio 45005 513-746-3603